Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meneveau

Showing results (271-280 of 290) with videos related to

Pageof 29
Sort By:
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|December 20, 2022
Recovery of right ventricular function after intermediate-risk pulmonary embolism: results from the multicentre Pulmonary Embolism International Trial (PEITHO)-2Anna C Mavromanoli, Stefano Barco, Walter Ageno, et al.
The Lancet. Haematology|August 7, 2021
Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trialFrederikus A Klok, Gerrit Toenges, Anna C Mavromanoli, et al.
The New England Journal of Medicine|April 11, 2014
Fibrinolysis for patients with intermediate-risk pulmonary embolismGuy Meyer, Eric Vicaut, Thierry Danays, et al.
Circulation|September 27, 2019
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS TrialStephan Windecker, Renato D Lopes, Tyler Massaro, et al.
Archives of Cardiovascular Diseases|April 30, 2021
ST-segment elevation myocardial infarction: Management and association with prognosis during the COVID-19 pandemic in FranceGuillaume Bonnet, Vassili Panagides, Mathieu Becker, et al.
Circulation|December 21, 2018
Five-Year Clinical Outcome and Valve Durability After Transcatheter Aortic Valve Replacement in High-Risk PatientsRomain Didier, Hélène Eltchaninoff, Patrick Donzeau-Gouge, et al.
JACC. Cardiovascular Interventions|July 18, 2021
TAVR Patients Requiring Anticoagulation: Direct Oral Anticoagulant or Vitamin K Antagonist?Romain Didier, Thibault Lhermusier, Vincent Auffret, et al.
Journal of the American College of Cardiology|October 8, 2016
Late Outcomes of Transcatheter Aortic Valve Replacement in High-Risk Patients: The FRANCE-2 RegistryMartine Gilard, Hélène Eltchaninoff, Patrick Donzeau-Gouge, et al.
Eclinicalmedicine|June 23, 2023
Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trialStéphane Zuily, Benjamin Lefèvre, Olivier Sanchez, et al.
The New England Journal of Medicine|May 4, 2012
Registry of transcatheter aortic-valve implantation in high-risk patientsMartine Gilard, Hélène Eltchaninoff, Bernard Iung, et al.
Pageof 29

Showing results (271-280 of 290) with videos related to

Sort By:
Pageof 29
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|December 20, 2022
Recovery of right ventricular function after intermediate-risk pulmonary embolism: results from the multicentre Pulmonary Embolism International Trial (PEITHO)-2Anna C Mavromanoli, Stefano Barco, Walter Ageno, et al.
The Lancet. Haematology|August 7, 2021
Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trialFrederikus A Klok, Gerrit Toenges, Anna C Mavromanoli, et al.
The New England Journal of Medicine|April 11, 2014
Fibrinolysis for patients with intermediate-risk pulmonary embolismGuy Meyer, Eric Vicaut, Thierry Danays, et al.
Circulation|September 27, 2019
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS TrialStephan Windecker, Renato D Lopes, Tyler Massaro, et al.
Archives of Cardiovascular Diseases|April 30, 2021
ST-segment elevation myocardial infarction: Management and association with prognosis during the COVID-19 pandemic in FranceGuillaume Bonnet, Vassili Panagides, Mathieu Becker, et al.
Circulation|December 21, 2018
Five-Year Clinical Outcome and Valve Durability After Transcatheter Aortic Valve Replacement in High-Risk PatientsRomain Didier, Hélène Eltchaninoff, Patrick Donzeau-Gouge, et al.
JACC. Cardiovascular Interventions|July 18, 2021
TAVR Patients Requiring Anticoagulation: Direct Oral Anticoagulant or Vitamin K Antagonist?Romain Didier, Thibault Lhermusier, Vincent Auffret, et al.
Journal of the American College of Cardiology|October 8, 2016
Late Outcomes of Transcatheter Aortic Valve Replacement in High-Risk Patients: The FRANCE-2 RegistryMartine Gilard, Hélène Eltchaninoff, Patrick Donzeau-Gouge, et al.
Eclinicalmedicine|June 23, 2023
Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trialStéphane Zuily, Benjamin Lefèvre, Olivier Sanchez, et al.
The New England Journal of Medicine|May 4, 2012
Registry of transcatheter aortic-valve implantation in high-risk patientsMartine Gilard, Hélène Eltchaninoff, Bernard Iung, et al.
Pageof 29